Economic and health impacts of infectious diseases in China: A protocol for systematic review and meta analysis

por Li, Meiyue, Fan, Danxue, Wang, Xiaowen
Publicado 2020

Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

por Weng, Xiuhua, Luo, Shaohong, Lin, Shen, Zhong, Lixian, Li, Meiyue, Xin, Rao, Huang, Pinfang, Xu, Xiongwei
Publicado 2020

Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion

por Li, Meiyue, Lin, Shen, Wilson, Leslie, Huang, Pinfang, Wang, Hang, Lai, Shubin, Dong, Liangliang, Xu, Xiongwei, Weng, Xiuhua
Publicado 2021

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

por Lin, Shen, Huang, Yaping, Dong, Liangliang, Li, Meiyue, Wang, Yahong, Gu, Dian, Wu, Wei, Nian, Dongni, Luo, Shaohong, Huang, Xiaoting, Xu, Xiongwei, Weng, Xiuhua
Publicado 2023

miR-508-3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7

por Guo, Fei, Zhang, Kai, Li, Meiyue, Cui, Lei, Liu, Guoyan, Yan, Ye, Tian, Wenyan, Teng, Fei, Zhang, Yanfang, Gao, Chao, Gao, Jinping, Wang, Yingmei, Xue, Fengxia
Publicado 2020